Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience, a global contract research organization (CRO) headquartered in San Diego, California in the United States, and a part of JSR Life Sciences and JSR Corporation, recently acquired by Japan Investment Corporation Capital Co., Ltd. (JICC), today announced an expansion of its facility in Singapore. This update includes new oncology research models and state-of-the-art imaging technologies. Located in the epicenter of Asia's biomedical sciences hub, the enhanced facility is set to bolster the company’s support for both global and local biotech and pharmaceutical companies engaged in preclinical and translational oncology drug discovery and development.
Opened in 2023, the Singapore facility enhances Crown Bioscience's strategic global presence, which spans 12 locations worldwide. Tapping into its prime location and strong partnerships with leading science and technology providers, the facility is now equipped with advanced Magnetic Resonance Imaging (MRI) for orthotopic and systemic models, In Vivo Imaging Systems (IVIS), and its transient human immunity platform (MiXeno™), alongside comprehensive biomarker services. It offers an extensive selection of oncology models, utilizing in vivo syngeneic, cell-derived xenograft (CDX), and patient-derived xenograft (PDX) models. The facility provides key analyses, including flow cytometry (FACS), ELISA assays, and tissue preservation (FFPE). These platforms and services are instrumental in the development and efficacy testing of novel oncology drugs and therapeutics.
John Gu, Interim CEO of Crown Bioscience, commented: “The expansion of our Singapore facility not only amplifies our oncology research capabilities but also reflects our strategic initiative to diversify our global operational bases and enhance accessibility in key regions. This ensures that we can continue to provide our clients with unmatched precision and efficiency in preclinical and translational drug research and development.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001076209/en/
Contacts
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Study Reveals Access to Emerging Technologies and Improved Security Are Driving Cloud Strategies as Global Enterprises Lay Foundation for GenAI1.10.2024 19:01:00 EEST | Press release
HCLTech, a leading global technology company, today released its report, ‘Cloud Evolution: Mandate to Modernize,’ offering a comprehensive analysis of how enterprises are reshaping their cloud strategies to drive innovation and business transformation. “Cloud is not just a technology investment; it is fundamental to how businesses modernize. The convergence of cloud, GenAI and the acceleration provided by cloud native practices is essential to how enterprises operate, enabling rapid decision-making, enhancing customer experiences and driving competitive advantage,” said Siki Giunta, Executive Vice President and Head of Cloud Native Center of Excellence, HCLTech. “Embracing cloud native architectures and platform engineering is essential for enterprises aiming to build a robust, future-proof IT landscape that supports continuous innovation. By refactoring applications and leveraging cloud native disciplines and practices, businesses can unlock unprecedented levels of agility, scalabilit
Berkshire Hathaway Specialty Insurance Announces Global and UK Casualty Promotions1.10.2024 18:03:00 EEST | Press release
Berkshire Hathaway Specialty Insurance (BHSI) today announced it has named Caroline Alder-Smurthwaite to its Global Underwriting Office for Casualty & Healthcare and promoted Charlotte Behar to succeed Caroline as Head of Casualty, UK. “Caroline has done an excellent job steering our casualty business in the UK, prioritizing consistency and stability for our customers and brokers,” said Hilary Browne, Deputy Global Chief Underwriting Officer, at BHSI. “I look forward to collaborating with Caroline in her new role as a member of our Global Underwriting Team as she works closely with our Casualty and Healthcare underwriting leaders throughout the world to ensure BHSI’s global approach to underwriting is understood and executed on, while at the same time tailored to local market characteristics. She leaves our UK Casualty business in excellent hands, with Charlotte ensuring a seamless transition, and bringing strong financial acumen, underwriting talent, and customer and broker relationsh
Antonio Marzia Appointed to Lead Topcon Agriculture as Executive Vice President and General Manager1.10.2024 17:28:00 EEST | Press release
Topcon Positioning Systems has announced the appointment of Antonio Marzia as executive vice president and general manager of Topcon Agriculture. Marzia succeeds Albert Zahalka — who has retired after a distinguished career with the company — and will report to Ivan Di Federico, president and CEO of Topcon Positioning Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240930081975/en/ Antonio Marzia (Photo: Business Wire) Marzia joined Topcon in 2018 as vice president of business solutions. Later, during his tenure as senior vice president and general manager of EMEA/APAC, he led several collaborative technology agreements with original equipment manufacturers (OEMs). “I am honored to lead Topcon Agriculture at such a pivotal time for precision agriculture,” said Marzia. “There is tremendous potential for growth, and I am committed to positioning Topcon as the preferred partner in this evolving landscape by fostering ra
Pure Lithium Expands Strategic Vanadium Cathode Technology Portfolio with Asset Acquisition from Private US Based Dimien Inc.1.10.2024 16:30:00 EEST | Press release
Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, is pleased to announce the acquisition of all the assets of Dimien Inc., a private U.S. vanadium cathode materials company. Pure Lithium acquired Dimien’s intellectual property, know-how, manufacturing equipment and took on its experienced team, accelerating the development of Pure Lithium’s lithium metal vanadium (LVO) battery. Dimien developed a class of vanadium-based cathode material known as zeta vanadium oxide (ZVO). This low-cost cathode material has high energy density and does not cause fires like today’s NMC and NCA cathodes. Dimien’s vanadium cathode is made from materials that are produced in North America and does not use minerals such as nickel, cobalt and graphite, which are sourced from less favorable jurisdictions, and are at risk of short supply in the future. Dr. Brian Schultz, Founder and CEO of Dimien, will join Pure Lithium in the role of Vice Presid
Suzano Completes the Acquisition of Two U.S. Industrial Facilities from Pactiv Evergreen1.10.2024 16:06:00 EEST | Press release
Suzano, the world's largest pulp producer, today completes the acquisition of two industrial assets from Pactiv Evergreen in Arkansas and North Carolina, United States. All conditions for completing the agreement announced in July have been fulfilled. The acquisition of the mills in Pine Bluff and Waynesville, that manufacture liquid packaging board and cupstock, adds approximately 420,000 metric tonnes annually of integrated paperboard to Suzano’s production capacity. The Brazilian company will now become a major supplier of papers used to produce Liquid Packaging Board in North America. Fabio Almeida, Executive Vice President of Paper and Packaging at Suzano and CEO of Suzano Packaging US, said: "We aim to scale our operations to meet the growing global demand for paper-based packaging. Our successful track record of asset integration gives us confidence that we will be able to enhance operational efficiency, production scale, and safety standards at these units, opening up new oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom